CN117157316A - 修饰的血浆凝血因子viii及其使用方法 - Google Patents

修饰的血浆凝血因子viii及其使用方法 Download PDF

Info

Publication number
CN117157316A
CN117157316A CN202180096784.0A CN202180096784A CN117157316A CN 117157316 A CN117157316 A CN 117157316A CN 202180096784 A CN202180096784 A CN 202180096784A CN 117157316 A CN117157316 A CN 117157316A
Authority
CN
China
Prior art keywords
leu
ser
glu
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180096784.0A
Other languages
English (en)
Chinese (zh)
Inventor
王启钊
于道展
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ainuojian Gene Therapy Co ltd
Original Assignee
Ainuojian Gene Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ainuojian Gene Therapy Co ltd filed Critical Ainuojian Gene Therapy Co ltd
Publication of CN117157316A publication Critical patent/CN117157316A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180096784.0A 2021-03-30 2021-03-30 修饰的血浆凝血因子viii及其使用方法 Pending CN117157316A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/024916 WO2022211791A1 (en) 2021-03-30 2021-03-30 Modified plasma clotting factor viii and method of use thereof

Publications (1)

Publication Number Publication Date
CN117157316A true CN117157316A (zh) 2023-12-01

Family

ID=75588282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180096784.0A Pending CN117157316A (zh) 2021-03-30 2021-03-30 修饰的血浆凝血因子viii及其使用方法

Country Status (4)

Country Link
EP (1) EP4314041A1 (https=)
JP (1) JP2024511851A (https=)
CN (1) CN117157316A (https=)
WO (1) WO2022211791A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
AU2003249208B2 (en) 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
SE536732C2 (sv) 2011-03-04 2014-07-01 Swemac Innovation Ab Protes för steloperation av en led
LT3013855T (lt) * 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
CN112119158A (zh) * 2018-04-12 2020-12-22 生物测试股份公司 去免疫化的因子viii分子以及包含其的药物组合物
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體

Also Published As

Publication number Publication date
EP4314041A1 (en) 2024-02-07
WO2022211791A1 (en) 2022-10-06
JP2024511851A (ja) 2024-03-15

Similar Documents

Publication Publication Date Title
JP7613759B2 (ja) ハンチントン病のａａｖ処置
AU2017248659B2 (en) Gene therapy for treating hemophilia A
CN113227385B (zh) 核酸分子及其用于非病毒基因疗法的用途
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
DK2698163T3 (en) Codon-optimized factor VIII variants and synthetic liver-specific promoter
US20220144919A1 (en) Mutant factor viii compositions and methods
AU2016343979A1 (en) Delivery of central nervous system targeting polynucleotides
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
CN114829391A (zh) 用肝特异性基因疗法载体治疗遗传性血管性水肿
CA2462966A1 (en) Factor viii c2 domain variants
AU2016348759B2 (en) AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and use thereof in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, inter alia
CN117157316A (zh) 修饰的血浆凝血因子viii及其使用方法
RU2812852C2 (ru) Невирусные днк-векторы и варианты их применения для экспрессии терапевтического средства на основе фактора viii (fviii)
US12583907B2 (en) Modified plasma clotting factor VIII and method of use thereof
RU2808564C2 (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение
HK40064488A (en) Mutant factor viii compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination